Last mentioned: Mar 5, 2026
Earnings Release
Both companies report Q4 and FY 2025 financial results and business highlights.
FDA Partial Hold
FDA notifies PepGen of partial clinical hold on Freedom2 trial.
Fiscal Year End
OmniAb and PepGen conclude their 2025 fiscal years.
OmniAb and PepGen reported full-year 2025 results, showcasing the health of the antibody discovery and neuromuscular therapeutics sectors. While OmniAb focuses on platform scalability and royalty streams, PepGen emphasizes clinical execution and cash preservation for its lead candidates.
OmniAb and PepGen have released their full-year 2025 financial results, highlighting a period of operational scaling and clinical advancement. While OmniAb continues to expand its antibody discovery ecosystem, PepGen is entering a critical phase with key data readouts expected in 2026 for its neuromuscular pipeline.
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
A trio of high-growth companies across genomics, biotechnology, and digital logistics are set to report quarterly results this Monday. Investors will be closely monitoring GeneDx's path to profitability, PepGen's clinical cash runway, and Freightos's transaction volume growth.
GeneDx (WGS) and PepGen (PEPG) are scheduled to release financial results on Monday, marking a pivotal moment for the clinical genomics and neuromuscular therapeutic sectors. Investors are looking for GeneDx to demonstrate a sustainable path to profitability through its whole genome sequencing volume, while PepGen's update will focus on its clinical pipeline and cash position.
GeneDx and PepGen are scheduled to report quarterly financial results on Monday, marking a pivotal moment for the genomic diagnostics and neuromuscular biotech sectors. Investors are looking for GeneDx's continued path toward profitability through whole genome sequencing and PepGen's clinical pipeline progress.
Freightos (CRGO) is set to report earnings this Monday, offering a critical window into the health of digital freight booking and global shipping rate transparency. As the industry grapples with post-pandemic normalization and geopolitical disruptions, the company's transaction volumes will serve as a bellwether for the logistics technology sector.